Elacestrant and Exemestane for HR+/HER2- Breast Cancer with FES-PET Positive Lesions

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial explores whether combining two endocrine therapies, elacestrant and exemestane, can benefit patients whose HR+/HER2- breast cancer has progressed after prior treatments. Eligibility requires measurable or evaluable bone disease and substantial lesion avidity on 18F-FES-PET imaging, indicating estrogen receptor expression. The study targets patients who are appropriate for endocrine therapy without immediate visceral crisis and who have progressed after CDK4/6 inhibitor-based therapy. The approach uses imaging-guided selection to identify those likely to respond to continued endocrine strategies. Outcomes will inform whether this combination can improve disease control with manageable toxicity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Must be at least 18 years old;
2. Must have a histologically- or cytologically-proven diagnosis of carcinoma of the breast with evidence of either locally advanced disease not amenable to resection or radiation therapy with curative intent or metastatic disease not amenable to curative therapy
3. Must be appropriate candidates for endocrine therapy (no visceral crisis, highly symptomatic disease or rapidly progressing disease)
4. Must have 1 of the following as defined by RECIST v1.1:

   1. Measurable disease
   2. Bone only disease with evaluable lesions. Subjects must have at least 1 lytic or mixed lytic/blastic bone lesion; blastic lesions only are not evaluable and allowed. Subjects who have had prior radiation to bone must have at least 1 evaluable lesion in a nonirradiated area.
5. ≥50% of measurable lesions defined as avid (SUVmax≥1.5) at 18F-FES-PET/CT;
6. Must have HR+ and HER2- disease at the last previous biopsy. ER and HER2 testing must be performed in the following manner:

   1. Documentation of ER+ tumor with ≥ 10% staining by immunohistochemistry (IHC), with or without PgR positivity AND
   2. Documentation of HER2- tumor with an IHC result of 0 or 1+ for cellular membrane protein expression or an in situ hybridization negative result as defined in the 2023 ASCO recommendations for HER2 testing (Wolff, 2013; Wolff, 2018; Wolff 2023)

8\. Must have progressed during or within 28 days of completion of prior treatment with a CDK4/6 inhibitor in combination with anastrozole or letrozole (+ LHRH agonist for male or premenopausal female patients).

1. This treatment has to be received in first line setting for metastatic disease (with abemaciclib, ribociclib or palbociclib)
2. Discontinuation of prior CDK4/6 inhibitor due to toxicity, in the absence of progression, will not fulfill this criterion
3. Patients must have received the combination treatment for at least 12 months and there must have been evidence of disease control (stable disease \[SD\], partial response \[PR\] or complete response \[CR\] as best response) 9. Must have received no other treatment after the CDK4/6 inhibitor combined with endocrine therapy 10. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Exclusion Criteria:

1. Prior treatment with fulvestrant, elacestrant or investigational SERD or ER antagonist in metastatic or early disease (e.g., D-0502, GDC-0810, GDC-0927, GDC-9545, G1T-48, LSZ102, AZD9496, SAR439859, ZN-c5, H3B-6545, bazedoxifene, lasofoxifene)
2. Prior treatment with tamoxifen or SERD alone or combined with CDK4/6i in metastatic setting
3. Any other endocrine therapy \< 14 days before first dose of study drug
4. Any prior treatment after first line with CDK4/6i in metastatic setting
5. Bisphosphonates or RANKL inhibitors initiated or dose changed \< 3 months prior to first dose of study drug
6. Radiation therapy within 14 days (28 days for brain lesions) before the first dose of study drug

Where it's running

• European Institute of Oncology
  Milan, Italy, Italy Recruiting

Study contacts

• Principal investigator: Giuseppe Curigliano — European Institute of Oncology
• Study coordinator: Giuseppe Curigliano, MD
• Email: giuseppe.curigliano@ieo.it
• Phone: 0257489439

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Gyrotonic exercise for elders with breast cancer and Behcet disease

  We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.

  Recruiting Cairo University · Giza, Dokki · NCT07929116

• PECS II vs SPSIP nerve blocks for pain after mastectomy

  This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.

  Recruiting Bursa City Hospital · Nilufer, Bursa · NCT07929090

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Compare a new endoscopy-assisted breast-conserving surgery with the usual approach

  This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.

  Recruiting Sir Run Run Shaw Hospital · Hangzhou, Zhejiang and 21 other locations · NCT07920094

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.